![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/23/2917127/0/en/FDA-Accepts-Mesoblast-s-Biologics-License-Application-BLA-for-Ryoncil-in-Children-With-Steroid-Refractory-Acute-Graft-Versus-Host-Disease-SR-aGVHD.html
https://www.globenewswire.com/news-release/2024/07/22/2916245/0/en/Patient-Enrollment-Commenced-in-Pivotal-Phase-3-Trial-of-Rexlemestrocel-L-for-Chronic-Low-Back-Pain.html
https://www.biospace.com/article/releases/mesoblast-resubmits-biologics-license-application-bla-with-united-states-food-and-drug-administration-fda-for-approval-of-ryoncil-in-children-with-steroid-refractory-acute-graft-versus-host-disease-sr-agvhd-/
https://www.globenewswire.com/news-release/2024/07/01/2906382/0/en/Mesoblast-to-File-Biologics-License-Application-for-Ryoncil-FDA-Approval-Next-Week.html
https://www.globenewswire.com/news-release/2024/06/03/2891870/0/en/Mesoblast-Corporate-Presentation-at-Investor-Conference.html
https://www.globenewswire.com/news-release/2024/04/30/2871764/0/en/Appendix-4c-Quarterly-Activity-Report-for-Quarter-Ended-March-31-2024.html
https://www.globenewswire.com/news-release/2024/03/26/2852084/0/en/United-States-Food-Drug-Administration-FDA-Notifies-Mesoblast-that-Available-Clinical-Data-from-Phase-3-Trial-Appear-Sufficient-to-Support-BLA-Submission-for-Remestemcel-L-in-Child.html
https://www.globenewswire.com//news-release/2024/03/13/2845924/0/en/Mesoblast-Successfully-Completes-Placement-and-Accelerated-Entitlement-Offer.html
https://www.globenewswire.com//news-release/2024/02/28/2837527/0/en/Mesoblast-Reports-Financial-Results-and-Operational-Update-for-Half-Year-Ended-December-31-2023.html
https://www.globenewswire.com//news-release/2024/02/15/2829545/0/en/United-States-Food-Drug-Administration-FDA-Grants-Mesoblast-Orphan-Drug-Designation-for-Revascor-Rexlemestrocel-L-in-Children-With-Congenital-Heart-Disease.html